Sign In  |  Register  |  About Walnut Creek Guide  |  Contact Us

Walnut Creek, CA
September 01, 2020 1:43pm
7-Day Forecast | Traffic

  • Search Hotels in Walnut Creek Guide

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Intercept Pharmaceuticals, Inc. - Common Stock (NQ: ICPT )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Nov 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Intercept Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
Hidden Gem Report: Intercept Pharma Ready To Explode
This biotech company is flying under the radar and could see easily 100% upside in the near-term based on both fundamental and technical signals. 
Via Talk Markets
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... 
Via Benzinga
Exposures Product Safety
Intercept Pharmaceuticals: Q2 Earnings Insights
Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) moved higher by 3.6% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share... 
Via Benzinga
Earnings Outlook For Intercept Pharmaceuticals
Intercept Pharmaceuticals (NASDAQ:ICPT) unveils its next round of earnings this Thursday, July 29. Get prepared with Benzinga's ultimate preview for Intercept Pharmaceuticals's Q2... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Acutus Medical (NASDAQ:AFIB) sto... 
Via Benzinga
Why Intercept Pharmaceuticals Stock Shed 19% of Its Value in the First Six Months of 2021
The biotech can't seem to catch a break. 
Via The Motley Fool
Exposures Product Safety
FDA Restricts Use Of Intercept's Ocaliva In Liver Disease with Advanced Cirrhosis Citing Risk Of Serious Liver Injury
The FDA has issued a statement restricting the use of Intercept Pharmaceuticals Inc’s (NASDAQ: ICPT) Ocaliva (obeticholic acid) in primary biliary... 
Via Benzinga
Exposures Product Safety
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start... 
Via Benzinga
Exposures Product Safety
Stocks That Hit 52-Week Lows On Wednesday
Wednesday morning, 20 companies set new 52-week lows. Interesting Facts: The largest company in terms of market cap to set a new 52-week low was Ionis... 
Via Benzinga
The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) I-Mab (NASDAQ: IMAB)... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Nabriva Jumps On Data, Larimar Wilts After Study Put On Hold, Travere To Delay Regulatory Filing
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 25) ESSA Pharma Inc. (NASDAQ:... 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Tuesday's morning session saw 16 companies set new 52-week lows. Noteworthy Points: The largest company in terms of market cap to set a new 52-week low was... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2021
Upgrades For Appian Corp (NASDAQ:APPN), Macquarie upgraded the previous rating of Underperform to Neutral. For the first quarter, Appian had an EPS of $0.06, compared to... 
Via Benzinga
The Daily Biotech Pulse: Pfizer In Vaccine Supply Talks With India, Provention In Focus Ahead Of Briefing Doc, NeuroRx To List Via SPAC Deal
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 24) Bristol-Myers Squibb Company... 
Via Benzinga
NGM Biopharma to Release Mid-Stage NASH Data Monday: What to Expect?
NGM Biopharmaceuticals, Inc. (NASDAQ: NGM) is a clinical-stage biopharma developing liver and metabolic disorders therapies. Its stock is down just 6.2% year-to-date... 
Via Benzinga
Intercept Pharmaceuticals Inc (ICPT) Q1 2021 Earnings Call Transcript
ICPT earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 11) HOOKIPA Pharma Inc. (NASDAQ... 
Via Benzinga
Exposures COVID-19
Stocks That Hit 52-Week Lows On Tuesday
Before 10 a.m. ET Tuesday, 173 stocks hit new 52-week lows. Intriguing Points: The largest company by market cap to set a new 52-week low was Snowflake (NYSE:SNOW... 
Via Benzinga
The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 10) AbbVie Inc. (NYSE: ABBV) -... 
Via Benzinga
Exposures COVID-19 Product Safety
The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 6) GT Biopharma, Inc. (NASDAQ:... 
Via Benzinga
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
Earnings Preview: Intercept Pharmaceuticals
Intercept Pharmaceuticals (NASDAQ:ICPT) unveils its next round of earnings this Thursday, May 06. Here is Benzinga's everything-that-matters guide for the earnings announcement.... 
Via Benzinga
With Important Trial Results Due in June, Is This Drugmaker a Good Buy Now?
The company faced challenges last year in expanding the label of its only drug. Will 2021 bring different results? 
Via The Motley Fool
Exposures Product Safety
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 WalnutCreekGuide.com & California Media Partners, LLC. All rights reserved.